Eli Lilly and Company $LLY Position Lowered by Factory Mutual Insurance Co.

Factory Mutual Insurance Co. reduced its position in Eli Lilly and Company (NYSE:LLY) by 4.4% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 86,500 shares of the company’s stock after selling 4,000 shares during the quarter. Eli Lilly and Company makes up about 0.7% of Factory Mutual Insurance Co.’s investment portfolio, making the stock its 29th biggest holding. Factory Mutual Insurance Co.’s holdings in Eli Lilly and Company were worth $67,429,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Brighton Jones LLC raised its position in shares of Eli Lilly and Company by 22.0% during the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock valued at $7,409,000 after acquiring an additional 1,730 shares in the last quarter. Revolve Wealth Partners LLC increased its stake in Eli Lilly and Company by 2.8% during the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock valued at $1,136,000 after purchasing an additional 40 shares during the last quarter. Covestor Ltd raised its holdings in shares of Eli Lilly and Company by 24.9% during the first quarter. Covestor Ltd now owns 426 shares of the company’s stock worth $352,000 after purchasing an additional 85 shares during the period. Kaufman Rossin Wealth LLC bought a new position in shares of Eli Lilly and Company in the 1st quarter worth about $242,000. Finally, Opes Wealth Management LLC lifted its position in shares of Eli Lilly and Company by 6.6% in the 1st quarter. Opes Wealth Management LLC now owns 337 shares of the company’s stock worth $278,000 after buying an additional 21 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analyst Ratings Changes

LLY has been the subject of a number of recent research reports. BMO Capital Markets boosted their price objective on shares of Eli Lilly and Company from $930.00 to $1,100.00 and gave the company an “outperform” rating in a research report on Thursday, November 6th. The Goldman Sachs Group upped their target price on Eli Lilly and Company from $876.00 to $879.00 and gave the company a “buy” rating in a report on Friday, October 10th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Eli Lilly and Company in a research report on Wednesday, October 8th. Daiwa Capital Markets lowered Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 price objective for the company. in a research report on Sunday, August 17th. Finally, Deutsche Bank Aktiengesellschaft dropped their target price on Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating on the stock in a research report on Monday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and seven have issued a Hold rating to the stock. According to data from MarketBeat, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus target price of $981.89.

Eli Lilly and Company Stock Performance

Shares of LLY stock opened at $965.68 on Tuesday. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $981.99. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. The firm has a market capitalization of $912.94 billion, a price-to-earnings ratio of 63.12, a price-to-earnings-growth ratio of 1.21 and a beta of 0.43. The business has a 50 day simple moving average of $804.63 and a 200 day simple moving average of $775.74.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company had revenue of $17.60 billion during the quarter, compared to analyst estimates of $16.09 billion. During the same quarter in the previous year, the firm posted $1.18 EPS. The firm’s quarterly revenue was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, equities research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be given a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date is Friday, November 14th. Eli Lilly and Company’s dividend payout ratio is currently 29.35%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.